Portal de Periódicos da CAPES

Evaluation of the Roche Cobas TaqMan and Abbott RealTime Extraction-Quantification Systems for HIV-1 Subtypes

2007; Lippincott Williams & Wilkins; Volume: 44; Issue: 5 Linguagem: Inglês

10.1097/qai.0b013e31803260df

1944-7884

Marie Gueudin, Jean‐Christophe Plantier, Véronique Lemee, Marie Paule Schmitt, Loïc Chartier, Thomas Bourlet, Annick Ruffault, Florence Damond, Muriel Vray, François Simon,

Molecular Biology Techniques and Applications

We conducted a comparison of the Abbott Molecular RealTime (Rungis, France) and Roche Diagnostics Cobas Taqman (Meylan, France) automated nucleic acid extraction and real-time polymerase chain reaction (PCR) amplification systems for their capacity to quantify HIV RNA of various subtypes. The systems were tested on culture supernatants belonging to HIV-1 group M (n = 29), HIV-1 group O (n = 8), and HIV-2 (n = 7). We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16]).The Abbott RealTime system quantified all 29 HIV-1 group M supernatants. One of these samples was not detected by the Roche Cobas TaqMan system. The Abbott RealTime system quantified 7 HIV-1 group O strains. Neither technique cross-reacted with HIV-2. The 79% intraclass correlation coefficient for the 88 plasma samples was barely acceptable, but 4 plasma samples were underestimated by more than 1 log by the Roche Cobas TaqMan system. Similar values were obtained for subtype B and D strains with the tests, indicating that the primers and probes are suitable for these strains. In contrast, the large differences observed with other subtypes, particularly CRF02, show the importance of primer and probe selection.The limitation of real-time PCR to span the entire diversity of HIV must be taken into account during treatment monitoring, resistance studies, and clinical trials.